-
Product Name
Anti-CD166/ALCAM antibody
- Documents
-
Description
Rabbit polyclonal to CD166/ALCAM
-
Tested applications
ELISA, WB, IP
-
Species reactivity
Cynomolgus CD166 / ALCAM
-
Alternative names
AI853494 antibody; ALCAM antibody; BEN antibody; CD166 antibody; DM-GRASP antibody; MGC27910 antibody; MuSC antibody; SC1 antibody; MEMD antibody; CD166 antibody; BEN antibody; SC1 antibody; MuSC antibody; CD166 antibody; AI853494 antibody; DM-GRASP antibody
- Immunogen
-
Isotype
Rabbit IgG
-
Preparation
Produced in rabbits immunized with purified, recombinant Cynomolgus CD166 / ALCAM (rh CD166 / ALCAM; G7NZQ8; Met1-Ala526). CD166 / ALCAM specific IgG was purified by Cynomolgus CD166 / ALCAM affinity chromatography.
-
Clonality
Polyclonal
-
Formulation
0.2 μm filtered solution in PBS
-
Storage instructions
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. -
Applications
WB: 5-10 μg/ml
ELISA:0.1-0.2 μg/mL
This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Cynomolgus CD166 / ALCAM. The detection limit for Cynomolgus CD166 / ALCAM is < 0.039 ng/well.
IP: 1-4 μg/mg of lysate
-
Validations
CD166 / ALCAM Antibody, Rabbit PAb, Antigen Affinity Purified, Western blot
CD166 / ALCAM Antibody, Rabbit PAb, Antigen Affinity Purified, Immunoprecipitation
-
Background
Activated leukocyte cell adhesion molecule (ALCAM)/Cluster of differentiation (CD166) is a type I transmembrane cell adhesion molecule belonging to the Ig superfamily and a ligand for CD6 that is expressed on T lymphocytes. The extracellular domain of ALCAM contains five Ig-like domains (three Ig-like C2-type domains and two Ig-like V-type domains), of which the amino-terminal V1 domain is essential for ligand binding and ALCAM-mediated cell aggregation. ALCAM mediates both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. ALCAM/CD6 interaction plays a role in T cell development and T cell regulation, as well as in the binding of T- and B-cells to activated leukocytes. Recently, homophilic (ALCAM-ALCAM) adhesion was shown to play important roles in tight cell-to-cell interaction and regulation of stem cell differentiation. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response and tumor progression. And CD166 is regarded as a potential novel breast cancer indicator and therapeutic target.
-
References
- Swart GW. (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 81(6): 313-21.
- Fujiwara H, et al. (2003) Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab. 88(7): 3437-43.
- Jezierska A, et al. (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 12(8): BR263-73.
- Kahlert C, et al. (2009) Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 101(3): 457-64.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"